Plasma Chromogranin a in Prostatic Carcinoma and Neuroendocrine Tumors
1997; Lippincott Williams & Wilkins; Volume: 157; Issue: 2 Linguagem: Inglês
10.1016/s0022-5347(01)65203-0
ISSN1527-3792
AutoresNoriko Kimura, Senji Hoshi, Masaru Takahashi, Satoshi Takeha, Soichiro Shizawa, Hiroshi Nagura,
Tópico(s)Neonatal Health and Biochemistry
ResumoNo AccessJournal of UrologyClinical Urology: Original Article1 Feb 1997Plasma Chromogranin a in Prostatic Carcinoma and Neuroendocrine Tumors Noriko Kimura, Senji Hoshi, Masaru Takahashi, Satoshi Takeha, Soichiro Shizawa, and Hiroshi Nagura Noriko KimuraNoriko Kimura , Senji HoshiSenji Hoshi , Masaru TakahashiMasaru Takahashi , Satoshi TakehaSatoshi Takeha , Soichiro ShizawaSoichiro Shizawa , and Hiroshi NaguraHiroshi Nagura View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)65203-0AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Chromogranin A is a good tumor marker for neuroendocrine cells. Whether plasma chromogranin A could be a useful marker for neuroendocrine differentiation of prostatic carcinoma and neuroendocrine tumors was investigated using an enzyme-linked immunosorbent assay. Materials and Methods: Plasma levels of chromogranin A were measured by enzyme-linked immunosorbent assay in 33 patients with prostatic carcinoma, 10 with benign prostatic hyperplasia (BPH) and 13 with neuroendocrine tumors (2 medullary thyroid carcinomas, 1 thymic carcinoid, 1 gastrin producing duodenal carcinoid, 3 nonfunctioning pancreatic endocrine tumors, 2 neuroblastomas, 3 pheochromocytomas and 1 carotid body tumor). Results: The normal level of chromogranin A from 40 healthy volunteers was 30 +/− 11 units per 1. (mean plus or minus standard deviation). Mean plasma chromogranin A in patients with BPH and prostatic carcinoma was 52.4 +/− 12.9 and 67.5 +/− 22.9 units per 1., respectively. All patients with neuroendocrine tumors, except 1 with a nonfunctioning pancreatic endocrine tumor, had elevated chromogranin A (mean 401 +/− 409 units per 1.). There were significant differences in plasma chromogranin A level between patients with BPH and neuroendocrine tumors (p <0.01), prostatic carcinoma and neuroendocrine tumors (p <0.01), and BPH and prostatic carcinoma (p <0.05). Of the 33 patients with prostatic carcinoma 5 had elevated chromogranin A, only 1 of whom had elevated prostate specific antigen. Conclusions: Chromogranin A is an excellent marker for neuroendocrine tumors, particularly nonfunctioning tumors, and measurement of chromogranin A is also useful to detect prostatic carcinoma in patients whose prostate specific antigen is not elevated. References 1 : Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulations. Nature1967; 215: 58. Google Scholar 2 : Chromogranin A-Its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr. Rev.1991; 12: 181. Google Scholar 3 : Immunohistochemical study of chromogranin in 100 cases of pheochromocytoma, carotid body tumour, medullary thyroid carcinoma and carcinoid tumour. Virchows Arch. A1988; 413: 33. Google Scholar 4 : Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J. Clin. Invest.1990; 85: 1555. Google Scholar 5 : Secretion of chromogranin A by peptide-producing endocrine neoplasms. New Engl. J. Med.1986; 314: 1145. Google Scholar 6 : How sensitive and specific is measurement of plasma chromogranin A for the diagnosis of neuroendocrine neoplasia? Ann. N. Y. Acad. Sci.1987; 493: 379. Google Scholar 7 : Hormone-negative, chromogranin A-positive endocrine tumors. New Engl. J. Med.1989; 320: 444. Google Scholar 8 : Source of plasma chromogranin A elevation in gastrinoma patients. Arch. Surg.1990; 125: 451. Google Scholar 9 : Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol.1993; 32: 161. Google Scholar 10 : Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Path. Res. Prac.1987; 182: 298. Google Scholar 11 : Neuroendocrine differentiation in carcinoma of the prostate-diagnostic, prognostic, and therapeutic implications. Cancer1992; 70: 254. Google Scholar 12 : Enzyme-linked immunosorbent assay for chromogranin A. Clin. Chem.1989; 35: 1934. Google Scholar 13 : Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans-correspondence in patients with neuroendocrine neoplasia. Neuropeptides1994; 26: 201. Google Scholar 14 : Expression of prohormone convertase, PC2, in ACTH-producing thymic carcinoid with elevated plasma corticotropin-releasing hormone. J. Clin. Endocr. Metab.1996; 81: 390. Google Scholar 15 : Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J. Urol.1994; 151: 914. Link, Google Scholar 16 : Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring-comparative study of a multiple tumor marker assay. Prostate1991; 19: 23. Google Scholar 17 : Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J. Urol.1991; 146: 358. Link, Google Scholar 18 : Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Archiv A1993; 423: 291. Google Scholar 19 Kimura, N., Miura, W., Noshiro, T., Mizunashi, K., Hanew, K., Shimizu, K., Watanabe, T., Shibukawa, S., Sohn, H. E., Abe, K., Miura, Y. and Nagura, H.: Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones. Endocr. J., in press. Google Scholar 20 : Serum chromogranin A in the differential diagnosis of Cushing's syndrome. Eur. J. Endocr.1994; 131: 589. Google Scholar Departments of Pathology and Urology, Tohoku University School of Medicine, and Department of Urology, Tohoku Rosai Hospital, Sendai, Japan.© 1997 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited ByISCHIA R, HOBISCH A, BAUER R, WEISS U, GASSER R, HORNINGER W, BARTSCH G, FUCHS D, BARTSCH G, WINKLER H, KLOCKER H, FISCHER-COLBRIE R and CULIG Z (2018) ELEVATED LEVELS OF SERUM SECRETONEURIN IN PATIENTS WITH THERAPY RESISTANT CARCINOMA OF THE PROSTATEJournal of Urology, VOL. 163, NO. 4, (1161-1165), Online publication date: 1-Apr-2000. Volume 157Issue 2February 1997Page: 565-568 Advertisement Copyright & Permissions© 1997 by American Urological Association, Inc.MetricsAuthor Information Noriko Kimura More articles by this author Senji Hoshi More articles by this author Masaru Takahashi More articles by this author Satoshi Takeha More articles by this author Soichiro Shizawa More articles by this author Hiroshi Nagura More articles by this author Expand All Advertisement PDF DownloadLoading ...
Referência(s)